Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.8
4.4
Journals
Cancers
Special Issues
Clinical Treatment and Prognosis of Breast Cancer
cancers-logo
Submit to Special Issue Submit Abstract to Special Issue Review for Cancers Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Clinical Treatment and Prognosis of Breast Cancer

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Clinical Research of Cancer".

Deadline for manuscript submissions: 31 July 2026 | Viewed by 7546

Special Issue Editors

Dr. Roxana Popescu

E-Mail Website1 Website2
Guest Editor
Cell and Molecular Biology Department, “Victor Babeș” University of Medicine and Pharmacy of Timișoara, 300041 Timișoara, Romania
Interests: cell biology; molecular biology; biomarkers
Special Issues, Collections and Topics in MDPI journals
Dr. Ionut Marcel Cobec

E-Mail Website
Guest Editor
1. ANAPATMOL Research Center, Faculty of Medicine, “Victor Babes” University of Medicine and Pharmacy Timisoara, 300041 Timisoara, Romania
2. Clinic of Obstetrics and Gynecology, Klinikum Freudenstadt, 72250 Freudenstadt, Germany
Interests: breast cancer; therapy; personalized therapy; gynecologic oncology; gynecologic cancers
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

We are pleased to invite you to contribute to the upcoming Special Issue Clinical Treatment and Prognosis of Breast Cancer. This Issue aims to bring together high-quality research and clinical insights that advance our understanding of modern breast cancer therapies, personalized treatment strategies, prognosis, survival and long-term patient outcomes.

Breast cancer remains one of the most common and complex malignancies worldwide, and continuous innovation in its treatment is essential. We welcome original research articles, comprehensive reviews, and clinical case studies that explore novel treatment approaches, predictive biomarkers, surgical techniques, patient management, and emerging therapies.

Our goal is to create a multidisciplinary platform for exchanging knowledge that can influence current practices and future directions in oncology. Your expertise and clinical experience would make a valuable contribution to this Special Issue.

We look forward to receiving your submissions and to collaborating on this important topic that affects millions globally.

With best regards,

Dr. Roxana Popescu
Dr. Ionut Marcel Cobec
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • breast cancer
  • targeted therapy
  • personalized therapy
  • alternative approach
  • tumor biology
  • gynecologic oncology

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (4 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

13 pages, 653 KB  
Review
Immunotherapies for Breast Cancer: From Checkpoint Inhibition to Emerging Cellular Therapies
by Ismini Tsagkaraki, Isaac Gannon, Alexandros Rampotas, Devika Singh, Harriet Roddy, Diego Ottaviani and Claire Roddie
Cancers 2026, 18(6), 911; https://doi.org/10.3390/cancers18060911 - 11 Mar 2026
Viewed by 992
Abstract
Breast cancer remains a leading cause of cancer-related morbidity and mortality worldwide, with therapeutic response being shaped by the unique biology of each breast cancer subtype. Immunotherapy has emerged as a transformative approach in selected disease subtypes, with the most successful results being [...] Read more.
Breast cancer remains a leading cause of cancer-related morbidity and mortality worldwide, with therapeutic response being shaped by the unique biology of each breast cancer subtype. Immunotherapy has emerged as a transformative approach in selected disease subtypes, with the most successful results being found in relation to triple negative breast cancer (TNBC). Immune checkpoint inhibitors (ICIs) have transformed the management of many solid tumours. In breast cancer, they have demonstrated clinical benefit in TNBC when combined with chemotherapy, establishing a new standard of care in both early-stage and metastatic settings. However, the majority of breast cancers exhibit intrinsic or acquired resistance to checkpoint blockade, driven by low tumour immunogenicity and an immunosuppressive tumour microenvironment. Recent advances in cellular immunotherapy could represent the next frontier in the therapeutic landscape of breast cancer. Chimeric antigen receptor (CAR) T cell targeting antigens such as HER2, ROR1, MUC1, mesothelin, and B7-H3 are entering early-phase clinical evaluation with results eagerly awaited. Parallel approaches, including tumour-infiltrating lymphocyte (TIL) therapy, T cell receptor (TCR)-engineered T cells, and CAR-natural killer (CAR-NK) platforms, offer alternative mechanisms to overcome antigen presentation barriers and immune evasion. This review summarises current clinical evidence for immunotherapies in breast cancer, highlights emerging cellular strategies, and discusses key challenges including antigen specificity, off-tumour toxicity, and tumour microenvironment-mediated resistance. Future progress will likely depend on rational combination approaches and next-generation engineered immune cell platforms to achieve durable and personalised clinical benefit. Full article
(This article belongs to the Special Issue Clinical Treatment and Prognosis of Breast Cancer)
►▼ Show Figures

Figure 1

12 pages, 261 KB  
Review
Efficacy and Safety of Selective Internal Radiation Therapy (SIRT) for Liver Metastases in Breast Cancer: An Umbrella Review
by Marco Cuzzocrea, Stefano Cappio, Marzia Conti Beltraminelli, Lorenzo Rossi, Chiara Martinello, Giorgio Treglia, Federico Pedersoli and Gaetano Paone
Cancers 2026, 18(5), 756; https://doi.org/10.3390/cancers18050756 - 26 Feb 2026
Viewed by 579
Abstract
Background/Objectives: Liver metastases in breast cancer patients are associated with poor prognosis and limited therapeutic options. Selective Internal Radiation Therapy (SIRT), also known as transarterial radioembolization (TARE), has emerged as a loco-regional treatment modality, particularly in cases refractory to systemic therapies. Objective [...] Read more.
Background/Objectives: Liver metastases in breast cancer patients are associated with poor prognosis and limited therapeutic options. Selective Internal Radiation Therapy (SIRT), also known as transarterial radioembolization (TARE), has emerged as a loco-regional treatment modality, particularly in cases refractory to systemic therapies. Objective: To systematically review and synthesize evidence from existing systematic reviews and meta-analyses on the efficacy and safety of SIRT in breast cancer patients with liver metastases. Methods: A comprehensive literature search was conducted in PubMed using predefined keywords related to SIRT and breast cancer, restricted to systematic reviews and meta-analyses. Inclusion criteria were reviews evaluating SIRT in breast cancer patients with hepatic metastases, reporting on efficacy (e.g., objective response rate, disease control rate, overall survival) and/or safety outcomes. The quality of included reviews was assessed using AMSTAR 2. Results: Seven systematic reviews and meta-analyses were included. Reported objective response rates (ORRs) ranged from 36% to 61%, and disease control rates (DCRs) from 78 to 96%. Toxicity profiles were generally favorable, with limited grade 3–4 adverse events. Some heterogeneity was noted in patient selection, types of microspheres used (glass vs. resin), and outcome definitions. Conclusions: SIRT appears to be a promising option for breast cancer patients with liver metastases, particularly in the setting of treatment resistance. However, heterogeneity among available studies and the lack of prospective randomized trials limit definitive conclusions. Further high-quality studies are warranted. Full article
(This article belongs to the Special Issue Clinical Treatment and Prognosis of Breast Cancer)
34 pages, 2625 KB  
Review
Nutritional Impact on Breast Cancer in Menopausal and Post-Menopausal Patients Treated with Aromatase Inhibitors
by Roxana Popescu, Corina Flangea, Daliborca Cristina Vlad, Ionut Marcel Cobec, Peter Seropian, Cristina Doriana Marina, Tania Vlad, Andrei Luca Dumitrascu and Daniela Puscasiu
Cancers 2026, 18(1), 73; https://doi.org/10.3390/cancers18010073 - 25 Dec 2025
Cited by 2 | Viewed by 1940
Abstract
Background/Objectives: Aromatase inhibitors (AIs)—specifically, letrozole, anastrozole and exemestane—represent the current gold standard for patients with estrogen-receptor-positive breast cancer (ER + BC). This narrative review highlights potential interactions between nutrients and AIs, elucidating their molecular mechanisms involved. Methods: A comprehensive search was [...] Read more.
Background/Objectives: Aromatase inhibitors (AIs)—specifically, letrozole, anastrozole and exemestane—represent the current gold standard for patients with estrogen-receptor-positive breast cancer (ER + BC). This narrative review highlights potential interactions between nutrients and AIs, elucidating their molecular mechanisms involved. Methods: A comprehensive search was conducted across the PubMed, ScienceDirect, Google Scholar, and Scopus databases to identify scientific publications and elucidate recommended dietary regimes for ER + BC patients treated with AIs. Results: Certain bioactive substances found in licorice, rosemary, juniper, cannabis, and citrus fruits exhibit intrinsic aromatase-inhibiting effects. Additionally, other nutrients and compounds—including honey, ginger, turmeric, sweet potatoes, pomegranates, bitter melon, dark sweet cherries, resveratrol, and vitamins D and C—contribute to treatment outcomes through their demonstrated antiproliferative properties. Certain natural compounds, such as soy, cow’s milk, sesame seeds, and sesame oil, require caution due to their potential estrogen-like effects which could diminish the anti-estrogenic efficacy of AIs. Conclusions: These considerations hold significant weight in this context, as the management of oncological patients—particularly women with ER + BC—requires an integrated perspective. Antineoplastic treatment must be supported by appropriate nutrition to enhance antitumor efficacy and improve the patient’s quality of life. The data presented herein are derived from in vitro, in silico, and animal model studies and await validation in large patient cohorts. Nevertheless, these findings pave the way for future research to elucidate these molecular phenomena in humans and to establish clinically significant conclusions for ER + BC patients. Full article
(This article belongs to the Special Issue Clinical Treatment and Prognosis of Breast Cancer)
►▼ Show Figures

Figure 1

23 pages, 659 KB  
Review
Trastuzumab–Deruxtecan for the Treatment of Metastatic Breast Cancer Patients: Data from Real World Studies
by Erica Quaquarini, Federica Luelli, Angioletta Lasagna, Gianpiero Rizzo, Lorenzo Perrone, Simone Figini, Raffaella Achille and Paolo Pedrazzoli
Cancers 2025, 17(21), 3505; https://doi.org/10.3390/cancers17213505 - 30 Oct 2025
Cited by 4 | Viewed by 3044
Abstract
Background: Trastuzumab–deruxtecan (T-DXd), a new-generation antibody drug conjugate, has greatly improved the survival and clinical benefit rates of patients affected by advanced HER2-positive/HER2-low breast cancer according to the results of controlled clinical trials with a manageable safety profile. Data from randomized clinical [...] Read more.
Background: Trastuzumab–deruxtecan (T-DXd), a new-generation antibody drug conjugate, has greatly improved the survival and clinical benefit rates of patients affected by advanced HER2-positive/HER2-low breast cancer according to the results of controlled clinical trials with a manageable safety profile. Data from randomized clinical trials can provide valuable information for the management of patients in everyday clinical practice, including those who would typically be excluded from such trials due to not meeting the inclusion criteria. Methods: In this narrative review, we describe and discuss real-world studies in the literature on the use of T-Dxd in HER2-positive and HER2-low MBC patients, providing a critical analysis of the specific settings of clinical interest. Results: Using a PubMed search, we identified nine real-world studies on T-DXd that are available in the literature. A total of 7146 patients have been included in these retrospective studies. A total of 5/9 studies also included HER2-low MBC patients. In the majority of cases, patients had high disease burden with lung and liver involvement. We then reviewed and discussed clinical areas of interest, including heavily pretreated patients, poor performance status, HER2-positive versus HER2-low disease, brain metastasis, elderly patients, lung toxicity, safety profile, and dose modifications. Conclusions: Our analysis confirms the activity of the drug described in real-world studies and shows a favorable safety profile, with manageable adverse effects. Full article
(This article belongs to the Special Issue Clinical Treatment and Prognosis of Breast Cancer)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-4
Back to TopTop